ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (ADCT) reported third-quarter 2026 net product revenue of $21.0 million, up from the same period in 2025. Revenue increased from $15.8 million, primarily on higher volume. GAAP net loss narrowed to $25.3 million, or $0.16 per share, from $41.0 million, or $0.30 per share.
An October restructuring included an $86.6 million PIPE financing, approximately 12.9 million common shares and 48 million warrants. Loan principal was reduced by $68.5 million to $50 million, and a $150 million change-of-control payment was eliminated. ADC Therapeutics expects cash runway into 2029; cash at September 30 was $189.2 million, versus $261.3 million at year-end 2025.
Tanabe submitted a Japanese marketing authorization application for ZYNLONTA and sublicensed commercialization to Nippon Shinyaku. Multiple ZYNLONTA abstracts, including five oral presentations, were accepted for ASH in December.
ADC Therapeutics (NYSE: ADCT) announced ZYNLONTA clinical results for presentation at the ASH Annual Meeting on December 12–15, 2026. In Phase 1b LOTIS-7, ZYNLONTA plus glofitamab produced an 88.7% overall response rate and 75.3% complete response rate among 97 efficacy-evaluable patients. In a Phase 2 marginal zone lymphoma study, those rates were 93% and 74.4% among 43 efficacy-evaluable patients; two-year progression-free survival was 90.8%.
In the 420-patient Phase 3 LOTIS-5 trial, ZYNLONTA plus rituximab improved median progression-free survival—time without disease worsening—to 6.14 months versus 4.73 months with R-GemOx. Overall survival did not differ statistically. Grade 5 adverse-event rates were 13.2% versus 4.6% within the protocol-defined 105-day reporting window, but 1.5% versus 3.0% using a 30-day post-treatment window. The company plans Phase 3 studies and is pursuing potential compendia and regulatory pathways.
ADC Therapeutics (NYSE: ADCT) will participate in two November investor conferences, with Chief Executive Officer Ameet Mallik speaking in fireside chats. The Guggenheim conference is November 10, 2026, at 1:30 p.m. EST in Boston. The Jefferies conference is November 19, 2026, from 1–1:25 p.m. GMT in London. Live webcasts will be available on the company’s investor website, with replays available for approximately 30 days after each event.
ADC Therapeutics (NYSE: ADCT) granted a new employee options to purchase 17,000 common shares as an employment inducement.
The grant was made on November 2, 2026, and approved by the board's Compensation Committee under the company's Inducement Plan. The options vest and become exercisable 25% on the first anniversary of the grant date, followed by 1/48th of the total award each month thereafter. Full vesting occurs on the fourth anniversary, subject to continued employment with the company.
ADC Therapeutics (ADCT) will announce its third-quarter 2026 financial results through a press release on November 9, 2026. The release will be available in the News section of the company's investor relations website at https://ir.adctherapeutics.com/news.
ADC Therapeutics (ADCT) announced that partner Tanabe Pharma filed for Japanese approval of ZYNLONTA for previously treated diffuse large B-cell lymphoma.
The application covers patients whose disease returned or resisted treatment after two or more lines of systemic therapy. In the Japanese Phase 2 study, the overall response rate was 58.1%, including a 41.9% complete response rate. Median response duration was not reached at a median follow-up of 15.21 months; no new safety concerns were identified.
Tanabe Pharma also signed an exclusive commercialization sublicense with Nippon Shinyaku for Japan. ADC Therapeutics' existing license includes near-term milestones tied to application filing acceptance and the first commercial sale in the Tanabe Pharma territory.
ADC Therapeutics (ADCT) announced an $86.6 million private placement alongside royalty and loan amendments intended to extend its expected cash runway into 2029. The financing comprises 12.9 million common shares at $1.42 and pre-funded warrants for 48.1 million shares at $1.32 each, with a CHF 0.08 exercise price. Closing is expected October 22, 2026.
The HCR amendment removes a $150 million change-of-control payment. A $70.0 million loan principal prepayment would leave $50.0 million due in August 2029, without scheduled amortization or a minimum liquidity covenant. Both amendments depend on the financing; HCR requires completion by October 31, 2026. Existing HCR and lender warrant exercise prices are reduced. ADC expects approximately $21.0 million in third-quarter ZYNLONTA net product revenue. September 30 cash was $189.2 million, or approximately $196 million pro forma for the financing and loan prepayment.
ADC Therapeutics (ADCT)/b) announced that CEO Ameet Mallik will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on Friday, September 11, 2026, at 9:10 a.m. ET.A live webcast and a 30-day replay will be accessible via the Investors section of the company’s website.
ADC Therapeutics (NYSE: ADCT) reported Q2 2026 net product revenue of $18.6 million (vs. $18.1 million in Q2 2025) and net loss of $16.6 million (vs. $56.6 million). License revenue was $0.6 million. Total operating expenses fell 29% to $44.7 million, driven mainly by lower R&D.
The company completed enrollment of the 100-patient LOTIS-7 trial of ZYNLONTA plus glofitamab and plans Breakthrough Therapy designation submissions. After an FDA pre-sBLA meeting raised benefit-risk concerns about the LOTIS-5 confirmatory trial, ADC Therapeutics is reassessing the regulatory path. Cash and equivalents were $219.1 million, with an expected runway at least into 2028. A strategic reorganization, including a 17% workforce reduction, is expected to deliver about $10 million in annualized cost savings.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report its second quarter 2026 financial results and provide operational updates.
Investors can access the call via registration and toll-free dial-in 1-800-836-8184 (North America/Canada) or through a live webcast under “Events and Presentations” in the Investors section at ir.adctherapeutics.com. An archived webcast will remain available for 30 days following the event.